Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Herpes simplex thymidine kinase (HStk) transgenic donor lymphocytes. Bone Marrow Transplant 1999 Nov;24(10):1043-51

Date

12/01/1999

Pubmed ID

10578153

DOI

10.1038/sj.bmt.1702020

Scopus ID

2-s2.0-0032732523 (requires institutional sign-in at Scopus site)   5 Citations

Abstract

Patients with recurrent leukemia after an allogeneic hematopoietic stem cell transplant may be treated with donor lymphocyte infusions (DLI). The transfusion of lymphocytes from the original hematopoietic stem cell donor induces remission in approximately one third of relapsed AML cases and 80% of relapsed CML. DLI may be complicated by delayed and sometimes lethal graft-versus-host disease (GVHD). In an attempt to avoid this complication, several centers have initiated DLI trials in which the infused lymphocytes carry a suicide gene, herpes simplex thymidine kinase (HStk), which confers sensitivity to ganciclovir (GCV). In the event of severe GVHD, administration of GCV should terminate or ameliorate GVHD.

Author List

Burt RK, Drobyski WR, Traynor AE, Link CJ Jr

Author

William R. Drobyski MD Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Ganciclovir
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Humans
Leukemia, Myeloid, Acute
Lymphocyte Transfusion
Simplexvirus
Thymidine Kinase
Transfection